Patent intelligence · US
US 10369182
Compositions and methods for treating insomnia and other sleep related disorders
Compositions and methods for treating insomnia and other sleep related disorders
Patent details — US 10369182
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2019
- Expiration
- Aug 1, 2039
- Applicant
- Script Essentials, LLC
- Claims
- 15
- CPC classes
- A61K, A61K31/00, A61K31/197, A61K31/198
Quick answer
US 10369182 (Compositions and methods for treating insomnia and other sleep related disorders) is held by Script Essentials, LLC. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Script Essentials, LLC
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/00, A61K31/197, A61K31/198, A61K31/4045, A61K31/405
More from Script Essentials, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10369182?
US 10369182 (Compositions and methods for treating insomnia and other sleep related disorders) is held by Script Essentials, LLC. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10369182?
Script Essentials, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10369182 expire?
Our index shows an expiration date of Aug 1, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.